Junta general de accionistas

Jul 15 2020

Por acuerdo del Consejo de Administración de Alternative Gene Expression S.L. (en lo sucesivo “Algenex”) se convoca Junta General de socios de Algenex, que tendrá lugar por vía telemática el día 30 de Julio de 2020, a las 10:00 horas.

Los datos de conexión a la reunión de la junta general de socios son los siguientes:

In accordance with the Board of Directors of Alternative Gene Expression S.L. (“Algenex”) we hereby convene a shareholder’s meeting to take place via videoconference on 30th July 2020 at 10:00am CET.

Please use the following link to patriciate in the meeting

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit

For further information, please contact:

Claudia Jiménez
General Manager
T: +34 91 452 4941